Understand the source comparison
Cagrilintide vs Ozempic: Which Works Better? | Real Peptides
Clinical trials published in Diabetes, Obesity and Metabolism found that cagrilintide monotherapy produced 10.8% mean body weight reduction at 32 weeks, while semaglutide (Ozempic/Wegovy) demonstrated 14.9% reduction at 68 weeks in the STEP-1 trial. But that s
No winner is assigned.
This page preserves a source comparison for education. It does not add a rating, recommendation or clinical judgment.
- Clinical trials published in Diabetes, Obesity and Metabolism found that cagrilintide monotherapy produced 10.8% mean body weight reduction at 32 weeks, while semaglutide (Ozempic/Wegovy) demonstrated 14.9% reduction at 68 weeks in the STEP-1 trial. But that stat alone misses the mechanism distinction that determines which compound suits which metabolic profile. Cagrilintide is an amylin receptor agonist; semaglutide is a GLP-1 receptor agonist. They don't compete. They work through entirely separate pathways, which is why dual-agonist research combining both mechanisms is producing the most dramatic results in obesity treatment history.
- Our team at Real Peptides has synthesized research-grade peptides for metabolic studies across hundreds of university labs. The gap between understanding these compounds on paper and preparing them correctly for actual research comes down to three things most supplier sites never explain: receptor specificity, plasma half-life variability, and what 'synergistic effect' actually means at the cellular level.
- What's the core difference between cagrilintide and Ozempic in weight loss mechanisms?
- Cagrilintide mimics amylin, a hormone co-secreted with insulin from pancreatic beta cells, binding to amylin receptors in the area postrema to suppress appetite and delay gastric emptying. While Ozempic (semaglutide) acts as a GLP-1 receptor agonist targeting hypothalamic satiety centers and slowing gut motility through vagal pathways. Both reduce caloric intake, but amylin agonism also blunts post-meal glucagon secretion (which GLP-1 agonists address indirectly), making cagrilintide particularly effective in insulin-resistant populations. The REWIND trial data suggests mean body weight reductions of 10–11% for cagrilintide monotherapy vs 12–15% for semaglutide 2.4mg weekly, but combination therapy trials show additive effects approaching 20%. Indicating the pathways don't overlap.
- The cagrilintide vs Ozempic comparison isn't about superiority. It's about pathway specificity. Semaglutide entered Phase III trials earlier and has FDA approval for obesity (as Wegovy); cagrilintide is currently in Phase II/III development but has shown tolerability profiles that differ meaningfully from GLP-1 agonists, particularly around nausea incidence during dose titration. This piece covers the receptor mechanisms driving each compound's effects, comparative efficacy data from named trials, side effect profiles at therapeutic doses, and what dual-agonist research (CagriSema) reveals about why combining both pathways produces results neither achieves alone.